
-
Kenya's economy faces climate change risks: World Bank
-
India's Modi in Sri Lanka for defence and energy deals
-
Fractious Republicans seek unity over Trump tax cuts
-
Trump's global tariff takes effect in dramatic US trade shift
-
'I don't have a voice in my head': Life with no inner monologue
-
Lula admits 'still a lot to do' for Indigenous Brazilians
-
California to defy Trump's tariffs to allay global trade fears
-
Sean 'Diddy' Combs faces more charges ahead of criminal trial
-
Intercommunal violence kills dozens in central Nigeria
-
Trump goads China as global trade war escalates
-
How can the EU respond to Trump tariffs?
-
Canada loses jobs for first time in 3 years as US tariffs bite
-
Nations divided ahead of decisive week for shipping emissions
-
US job growth strong in March but Trump tariff impact still to come
-
Stocks, oil slump as China retaliates and Trump digs in heels
-
US hiring beats expectations in March as tariff uncertainty brews
-
Where things stand in the US-China trade war
-
UK spy agency MI5 reveals fruity secrets in new show
-
Taiwan earmarks $2.7 bn to help industries hit by US tariffs
-
Greece nixes Acropolis shoot for 'Poor Things' director
-
Trump unveils first $5 million 'gold card' visa
-
BP chairman to step down after energy strategy reset
-
Indian patriotic movie 'icon' Manoj Kumar dies aged 87
-
Pacific nations perplexed, worried by Trump tariffs
-
Prominent US academic facing royal insult charge in Thailand
-
Yana, a 130,000-year-old baby mammoth, goes under the scalpel
-
Crops under threat as surprise March heatwave hits Central Asia: study
-
Japan PM says Trump tariffs a 'national crisis'
-
'It's gone': conservation science in Thailand's burning forest
-
EU leaders push for influence at Central Asia summit
-
Asian stocks extend global rout after Trump's shock tariff blitz
-
German industry grapples with AI at trade fair
-
Where Trump's tariffs could hurt Americans' wallets
-
Trump tariffs on Mexico: the good, the bad, the unknown
-
With tariff war, Trump also reshapes how US treats allies
-
Penguin memes take flight after Trump tariffs remote island
-
Tom Cruise pays tribute to Val Kilmer
-
'Everyone worried' by Trump tariffs in France's champagne region
-
UK avoids worst US tariffs post-Brexit, but no celebrations
-
Canada imposing 25% tariff on some US auto imports
-
Lesotho, Africa's 'kingdom in the sky' jolted by Trump
-
Trump's trade math baffles economists
-
Macron calls for suspension of investment in US until tariffs clarified
-
Trump tariffs hammer global stocks, dollar and oil
-
Mexico president welcomes being left off Trump's new tariffs list
-
Lesotho hardest hit as new US tariffs rattle Africa
-
Stellantis pausing some Canada, Mexico production over Trump auto tariffs
-
Rising odds asteroid that briefly threatened Earth will hit Moon
-
Is the Switch 2 worth the price? Reviews are mixed
-
Countries eye trade talks as Trump tariff blitz roils markets
RBGPF | 100% | 69.02 | $ | |
SCS | -0.56% | 10.68 | $ | |
BCC | 0.85% | 95.44 | $ | |
NGG | -5.25% | 65.93 | $ | |
AZN | -7.98% | 68.46 | $ | |
RELX | -6.81% | 48.16 | $ | |
GSK | -6.79% | 36.53 | $ | |
CMSC | 0.13% | 22.29 | $ | |
RIO | -6.88% | 54.67 | $ | |
JRI | -7.19% | 11.96 | $ | |
BCE | 0.22% | 22.71 | $ | |
CMSD | 0.7% | 22.83 | $ | |
RYCEF | -18.79% | 8.25 | $ | |
VOD | -10.24% | 8.5 | $ | |
BTI | -5.17% | 39.86 | $ | |
BP | -10.43% | 28.38 | $ |

Once-taboo ketamine booms for US at-home mental care
Americans are paying to get a star of the psychedelic medicine movement –- ketamine -– shipped to them for at-home mental health treatments that are being called both a breakthrough and a gamble.
A pandemic-spurred easing of prescription rules helped fuel a jump in telemedicine offerings of ketamine, an anesthetic that was once a taboo party drug but has become a buzzed-about tool against depression.
Yet long-term, large-scale studies of ketamine's medical impact are limited, leaving some experts concerned that an unregulated online boom could result in mishaps or a regulatory crackdown.
"This has to be rolled out slowly," said Boris Heifets, a Stanford University assistant professor of anesthesiology. "The risk is that we are scaling the fix but not the solution, which is a much more integrated approach to mental health."
Ketamine has been available in the United States since the 1970s as an anesthetic called a "dissociative" because of the hallucinogenic effects that have helped make it a rave culture drug.
It's legal for US doctors to prescribe, while some other psychedelics getting renewed attention for mental health uses like LSD or MDMA (also called ecstasy) are classified as having no medical utility and a high risk for abuse.
In this context, recent years have seen an uptick in clinics offering in-person intravenous ketamine treatments for depression, anxiety or chronic pain, though regulations and practices vary across American states.
- Ketamine 'babysitter' -
Then came the pandemic, which resulted in US authorities allowing doctors to remotely prescribe drugs like ketamine that previously required an in-person visit.
An increasing number of companies, some already doing in-clinic treatments, began offering to evaluate clients online and to send the drugs for home use to approved candidates.
Nue Life, which launched about a year ago, is one of those firms. Its CEO Juan Pablo Cappello estimated it has served over 3,000 ketamine patients so far.
"If you actually drill down on the sort of potentials for abuse here, you realize of course they exist, but we're creating a standard of care to make that quite unlikely," he told AFP.
For example, he noted clients are instructed to have an adult "babysitter" watch over them for the roughly 90 minutes the drug experience lasts, and he reasoned that people simply looking for ketamine could get it cheaper on the street.
Clients of the service, which costs $1,250 for a package providing six ketamine experiences, are encouraged but not obligated to couple it with therapy, Cappello said.
"The at-home telemedicine model, I would argue, is actually safer and more effective for patients," allowing more patients "to actually take advantage of these therapies," he added.
Heifets, the Stanford researcher, noted that making ketamine more available carries risks -- including the chances that authorities would tighten access if an at-home treatment resulted in some sort of tragedy.
- 'Change your life' -
US regulators in 2019 approved a type of ketamine specifically for adults with treatment-resistant depression, though with stringent rules like requiring patients to be monitored by a health care provider for at least two hours after their dose.
Americans have "a hair trigger for problem-solving through litigation," Heifets noted of the potential for lawsuits if things go wrong.
He was part of a team that analyzed the real-world effectiveness of intravenous ketamine therapy -- which can involve higher doses than the at-home services –- and reported most patients improved, though about eight percent said depressive symptoms worsened after treatment.
"We have very, very little evidence for our understanding of how effective ketamine is for depression at scale," he added.
Yet for people like 36-year-old New Yorker Philip Markle, who underwent an at-home treatment with a company called Mindbloom, ketamine is a profoundly useful tool.
Over his long battle with depression, the performer and comedian has tried medication, psychedelics like LSD, and talk therapy since the age of 12, but found something unique in ketamine.
Rather than the short-lived sense of change other treatments provided, ketamine imparted a sense of clarity and of helpful self-acceptance -– not the heavy effects he'd experienced with other psychedelics.
"It felt like if any drug could be administered through the mail, and you could do a psychedelic that could change your life, on your own, this would be the one," he told AFP.
M.Davis--CPN